In-depth quantification and characterisation of PI 3kinase signalling networks

Lead Research Organisation: Queen Mary University of London
Department Name: Sch of Medicine & Dentistry

Abstract

We work on a group of signal transduction proteins called phosphoinositide 3-kinases (or PI3Ks in short) that play important roles in many biological functions in the healthy organism, and are also implicated in diseases such as diabetes, allergy, and cancer. There are 8 different PI3K genes and it is becoming clear that they have different functions and that they are involved in different diseases. The delineation of the roles of PI3K genes not only has purely academic importance in providing insight into fundamental biological processes but is also of huge interest for the ongoing development of drugs that inhibit specific forms of PI3Ks to treat different diseases. Despite many recent scientific advances in the field, there is little information on how the different forms of PI3K perform their distinct biological functions. The hypothesis we would like to test is that the different PI3Ks differ in the way by which they affect a group of proteins called protein kinases and their substrates. To test this hypothesis we will use a novel method that we have developed in the laboratory, based on a technique known as mass spectrometry, to quantify how active protein kinase pathways are in cells. The advantage of mass spectrometry is that it analyses the activities of protein kinases in a comprehensive fashion, allowing to quantify thousands of activities simultaneously. This depth of analysis is allowing us to quantify protein kinase activity without preconceptions of which of the many kinases in cells may or may not be affected by PI3K. It therefore also allows to discover unknown mechanisms of PI3K signal transduction. In the work proposed in this application we will inactivate the different PI3Ks in cells by pharmacological and genetic means, and compare to normal or untreated cells. The focus of this work will be on 3 different PI3Ks known as p110alpha, p110beta and p110delta. These results are likely to lead to the discovery of pathways specifically affected by the different PI3K genes. These results would be of high impact in the field and also allow to discover markers for drugs that inhibit these PI3Ks selectively. The second stage of the project involves investigating the role of these newly identified proteins as potential players in the function of PI3K, which will be achieved by standard genetic and biochemical approaches in cell-based studies.

Technical Summary

This proposal offers a timely opportunity of combining unique expertise in analytical cell signalling and PI3K biology, now that the required technologies and genetic and pharmacological tools have matured to a level that can be used to start to address key questions in the field. There are 8 catalytic isoforms of PI3K and the creation of gene-targeted mice and pharmacological inhibitors with specificity for the different isoforms are contributing to the understanding of the biological functions of the different isoforms. Despite this information, little is known about the mechanisms by which distinct PI3K isoforms exert their non-redundant functions. The aim of this proposal is to investigate how inactivation of specific isoforms of the class IA subset of PI3Ks affects the activity of downstream protein kinases. For this, we will use a technique, based on mass spectrometry, for in-depth quantification of kinase activities. This method quantifies peptides bearing sites of phosphorylation. Our preliminary data indicate that it is possible to quantify thousands of phosphorylated sites with time frames compatible with the use of the technique as a 'routine' readout of biological experiments. Cells will be exposed to pan and isoform-selective PI3K inhibitors; phosphorylated sites will then be quantified with our techniques for in-depth analysis of kinase activities. Other experiments will involve comparing kinase activities in fibroblasts with genetic inactivation of Class IA PI3K isoforms with their wild-type counterparts. The second stage of the project involves validation of the mass spectrometry experiments using standard biochemical techniques and to address the role of selected novel PI3K pathway members in signalling and cell biology. These experiments are likely to provide novel information on how the PI3K pathway operates and could lead to the identification isoform-specific PI3K signalling pathways for the first time.

Publications

10 25 50

publication icon
Beltran L (2011) Calpain interacts with class IA phosphoinositide 3-kinases regulating their stability and signaling activity. in Proceedings of the National Academy of Sciences of the United States of America

publication icon
Cutillas PR (2015) Role of phosphoproteomics in the development of personalized cancer therapies. in Proteomics. Clinical applications

publication icon
Cutillas PR (2011) Biological signalling activity measurements using mass spectrometry. in The Biochemical journal

 
Description During this grant we developed and refined methodology to quantify kinase signalling. We used these methods to discover biochemical pathways downstream of an enzyme named phosphoinositide 3-kinase. We also discovered unexpected connections between different pathways in the biochemical network that regulates cell behaviour. The methodology created as part of this work was used to create a spin-out company.
Exploitation Route The methods created as part of this work could be used by others to discover new drug targets and biomarkers for personalising therapies based on kinase inhibitors.
Sectors Digital/Communication/Information Technologies (including Software),Healthcare,Pharmaceuticals and Medical Biotechnology

 
Description Research from this laboratory resulted in the creation of a spin-out company that served the pharma and biotech sector, created jobs, and is now being used to identify biomarkers and drug targets of respiratory disease. This can benefit society in the future.
First Year Of Impact 2014
Sector Pharmaceuticals and Medical Biotechnology
Impact Types Societal,Economic,Policy & public services

 
Description European Marie Curie Fellowship
Amount £110,000 (GBP)
Funding ID PIIF-GA-2009-252846 
Organisation European Commission 
Sector Public
Country European Union (EU)
Start 01/2011 
End 12/2012
 
Description Research Grant
Amount £490,000 (GBP)
Organisation Barts Charity 
Sector Charity/Non Profit
Country United Kingdom
Start 03/2009 
End 09/2014
 
Title Computational method to analyse mass spectrometry data 
Description This is a method to quantify cell signalling based on the analysis of mass spectrometry data with software created specifically for this purpose. 
Type Of Material Technology assay or reagent 
Year Produced 2011 
Provided To Others? Yes  
Impact The method was used as a core aspect of Activiomics, a spin-out company from QMUL. It is now licensed to hVivo. 
 
Title Computational method to quantify kinase activity 
Description This is a method to quantify kinase activity from large phosphoprotemics data. 
Type Of Material Technology assay or reagent 
Year Produced 2014 
Provided To Others? Yes  
Impact The method, named KSEA, was published in 2013 (Casado et al Science Sig, PMID:23532336) and we have used it to discover new aspects of cells biology in our own research projects (e.g., Rajeeve et al 2014, PMID:24648465) as well as with collaborators (e.g., Herranz et al Nat Cell Biol 2015, PMID:26280535). We are also using KSEA with industrial partners (ProteomeSciences). 
 
Title METHOD 
Description The present invention provides a method of quantifying the activity of a protein modifying enzyme in a sample, comprising: (i) grouping modified peptides from a first sample and modified peptides from a second sample into a single group according to one of the following parameters: (a) modified peptides having a modification site that is modified by the same protein modifying enzyme; or (b) modified peptides having a modification site that is part of the same modification motif; (ii) calculating enrichment of the modified peptides from the first sample compared to the modified peptides from the second sample in the group; and (iii) calculating the statistical significance of said enrichment; wherein a statistically significant enrichment is indicative of a protein modifying enzyme being activated in the first sample compared to the second sample. In some embodiments, the method further comprises identifying modified peptides in a first sample and a second sample using mass spectrometry (MS) prior to step (i). 
IP Reference WO2013132075 
Protection Patent application published
Year Protection Granted 2013
Licensed Commercial In Confidence
Impact The discovery is being evaluated in broader contexts than originally published as a means to infer the most appropriate targeted compound in individual cancer patients.
 
Title METHOD FOR IDENTIFYING ACTIVATION OF TRANSFERASES 
Description The present invention provides a method for identifying differential activation of a bisubstrate protein modifying enzyme between samples, comprising: (i) incubating a first sample with x different concentrations of the non-protein substrate of said enzyme, wherein x is 2 or greater than 2; (ii) quantifying modification of a polypeptide in said sample at each of the x different concentrations of the non-protein substrate; (iii) determining the affinity of said enzyme for said non-protein substrate; (iv) repeating steps (i) to (iii) for a second or subsequent sample; and (v) comparing the affinity of said enzyme for said non-protein substrate between said samples; wherein a difference in affinity of said enzyme for said non-protein substrate between samples is indicative of differential activation of said enzyme between samples. The present invention also provides a method for identifying an in vivo substrate of a bisubstrate protein modifying enzyme. 
IP Reference WO2012052711 
Protection Patent application published
Year Protection Granted 2012
Licensed Yes
Impact Licensed to Activiomics Ltd
 
Title METHOD FOR IDENTIFYING QUANTIFIABLE PEPTIDES 
Description The present invention provides a method of identifying a target peptide for quantification by mass spectrometry (MS), comprising: (i) mixing peptides from a pair of samples at y different ratios to produce y mixtures, wherein y is 2 or greater than 2; (ii) carrying out MS on each of the y mixtures to determine the ionic intensity of a peptide in each of the y mixtures; (iii) calculating the relative ionic intensity of said peptide in each of the y mixtures by comparing the ionic intensity of said peptide in each of the y mixtures to the maximum ionic intensity of said peptide across all of the y mixtures; and (iv) correlating the relative ionic intensity of said peptide in each of the y mixtures with the change in composition of the y mixtures; wherein if the relative ionic intensity of said peptide is directly proportional to the change in composition of the y mixtures, said peptide is a target peptide for quantification by MS. 
IP Reference WO2011128648 
Protection Patent application published
Year Protection Granted 2011
Licensed Yes
Impact Licensed to Activiomics Ltd for 2 years, subsequently dropped.
 
Title METHOD FOR QUANTIFYING MODIFIED PEPTIDES 
Description The present invention provides a method for quantifying modified peptides in a sample, the method comprising: (a) obtaining peptides from the sample; (b) adding reference modified peptides to the peptides obtained in step (a) to produce a mixture of peptides and reference modified peptides; (c) carrying out mass spectrometry (MS) on said mixture of peptides and reference modified peptides to obtain data relating to the peptides in the sample; and (d) comparing the data relating to the peptides in the sample with data in a database of modified peptides using a computer programme; wherein the database of modified peptides is compiled by a method comprising: (i) obtaining peptides from a sample; (ii) enriching modified peptides from the peptides obtained in step (i); (iii) carrying out liquid chromatography-tandem mass spectrometry (LC- MS/MS) on the enriched modified peptides obtained in step (ii); (iv) comparing the modified peptides detected in step (iii) to a known reference database in order to identify the modified peptides; and (v) compiling data relating to the modified peptides identified in step (iv) into a database. 
IP Reference WO2010119261 
Protection Patent application published
Year Protection Granted 2010
Licensed Yes
Impact This research output was licences to Activiomics Ltd, a spin out company from QMUL which was receently acquired by Retroscreen Virology Group.
 
Title Pescal 
Description Pescal is a software to analyse mass spectrometry data. 
Type Of Technology Software 
Year Produced 2007 
Impact This software was licensed to Activiomics Ltd, and was key in the business of the company. 
 
Company Name Activiomics Ltd 
Description Activiomics Ltd is a privately owned spin-out company from the Barts Cancer Institute that uses mass spectrometry based technology developed, in part, with work from this award. The company currently employs three people full time and two part time. Activiomics offers mass spectrometry based services to the pharmaceutical and biotechnology industry, and so far it has had contracts from, among others, GSK, UCB and Genentech. 
Year Established 2011 
Impact Activiomics successfully completed contract research with several biotech companies. Recently the company has been acquired by Retroscreen Virology Group for £4M and it now focuses on the identification of biomarkers and drug targets for respiratory disease.
Website http://www.activiomics.com/default.asp?id=1
 
Company Name Kinomica Ltd 
Description Kinomica seeks to develop and commercialise companion diagnostic tests based on technology developed at QMUL. 
Year Established 2016 
Impact In the last 18 months Kinomica received £970,000 of seed funding and £3.9M Series A funding. This is allowing the company to commercialise outputs from this research.